Taïeb, David
Nölting, Svenja
Perrier, Nancy D.
Fassnacht, Martin http://orcid.org/0000-0001-6170-6398
Carrasquillo, Jorge A. http://orcid.org/0000-0002-8513-5734
Grossman, Ashley B. http://orcid.org/0000-0003-1176-6186
Clifton-Bligh, Roderick http://orcid.org/0000-0002-1545-0368
Wanna, George B.
Schwam, Zachary G.
Amar, Laurence http://orcid.org/0000-0003-3942-4276
Bourdeau, Isabelle
Casey, Ruth T.
Crona, Joakim http://orcid.org/0000-0003-0677-4894
Deal, Cheri L. http://orcid.org/0000-0001-6434-2745
Del Rivero, Jaydira
Duh, Quan-Yang
Eisenhofer, Graeme
Fojo, Tito
Ghayee, Hans K.
Gimenez-Roqueplo, Anne-Paule http://orcid.org/0000-0002-4816-670X
Gill, Antony J.
Hicks, Rodney
Imperiale, Alessio
Jha, Abhishek http://orcid.org/0000-0002-1489-2471
Kerstens, Michiel N.
de Krijger, Ronald R.
Lacroix, André http://orcid.org/0000-0003-4137-3025
Lazurova, Ivica
Lin, Frank I.
Lussey-Lepoutre, Charlotte http://orcid.org/0000-0003-2228-0106
Maher, Eamonn R. http://orcid.org/0000-0002-6226-6918
Mete, Ozgur
Naruse, Mitsuhide
Nilubol, Naris
Robledo, Mercedes http://orcid.org/0000-0001-6256-5902
Sebag, Frédéric
Shah, Nalini S.
Tanabe, Akiyo http://orcid.org/0000-0002-5682-4952
Thompson, Geoffrey B.
Timmers, Henri J. L. M.
Widimsky, Jiri
Young, William J. Jr
Meuter, Leah
Lenders, Jacques W. M. http://orcid.org/0000-0002-7658-4466
Pacak, Karel http://orcid.org/0000-0002-3541-3767
Article History
Accepted: 16 November 2023
First Online: 14 December 2023
Competing interests
: D.T. has received personal honoraria for lectures and consulting from AAA/Novartis and support for meeting attendance from AAA/Novartis. S.N. has received research contracts from Novartis, lecture fees from Ipsen, and support for meeting attendance from Novartis and Ipsen. A.B.G. has received lecture fees from AAA/Novartis and Advisory Board fees from Ipsen. Z.G.S. is a paid consultant for Acclarent. L.A. has received personal honoraria for lectures from Servier and Ipsen. R.T.C. has received personal honoraria for lectures from Novartis, support for meeting attendance from Ipsen, and serves as a board member on the clinical committees for the Society for Endocrinology and UK and Ireland Neuroendocrine Tumour Society. R.H. is a shareholder in Telix Pharmaceuticals and PreMIT Pty Ltd. C.L.-L. has received personal honoraria for lectures from Ipsen and support for meeting attendance from Ipsen. E.R.M. has received fees for consulting from MSD and personal honoraria for lectures from MSD. M.N. has received personal honoraria for lectures from PDRadiopharma Inc. N.N. has received an intramural research grant from the NIH. The other authors declare no competing interests.
Free to read: This content has been made available to all.